Stock Market News
Stay updated with the latest stock market news and insights
Stay updated with the latest stock market news and insights
Stay updated with the latest stock market news and insights
The White House has vetted candidates for four vacant CFTC seats, but nominations are stalled, leaving the agency with just one commissioner ahead of a key crypto vote.
The former congresswoman says the Russia/Ukraine and Iran conflicts are driving fuel costs to historic highs, and she's not holding back.
Trump plans to spend up to $500 million to boost Republicans in the 2026 midterms, while Elon Musk could add another $100 million-plus.
President Trump announces tariff-free beef from Brazil and Argentina to combat record prices, while targeting meat processors and expanding DOJ scrutiny to retailers.
Wyden and Harrigan are questioning whether the U.S. military has done enough to protect troops from commercial location tracking.
A closer look at where ETF money went in August reveals a surprising shift beneath the market’s biggest investment trends.
A congressman is buying up more Apple stock, even with a major CEO transition happening this month.
August payrolls surged to 162,000, tripling expectations and pushing September rate-hike odds to 60%. Yet stocks held firm, buoyed by a record earnings season and Dell's AI-fueled blowout.
A congressman's recent trades show him swapping one Magnificent Seven stock for another, with the sale of Apple coming just before a leadership transition.
Lululemon's margin pressure raises concerns for consumer ETFs as weak sales, tariffs, and competition test retail profitability.
The White House launched a new set of arcade-style games to highlight President Trump's policies, but the games look a lot like classic titles. Here's what's going on.
A stronger-than-expected jobs report has revived talk of Fed rate hikes. While that spooks growth stocks, certain ETFs are built to thrive in a higher-rate world.
Figure's 100,000-GPU deal shows Nvidia's next AI growth driver may be humanoid robots, not just chatbot makers.
Canaccord Genuity starts Belite Bio (BLTE) with a Buy and a $303 target, betting big on tinlarebant's potential in Stargardt disease and beyond.
A blowout August jobs report pushed traders to price a coin-flip chance of a Federal Reserve rate hike this month, dragging the S&P 500 and Dow lower by midday Friday.